Introduction to peripheral T cell lymphoma

Introduction Peripheral T-cell lymphoma accounts for 7% of all non-Hodgkin lymphoma (NHL) cases. Its diagnosis relies mainly on professional blood pathologists based on appropriate biopsy pathology and immunophenotype. The first-line treatment of peripheral T-cell lymphoma includes CHOP, etc. Young patients often consider hematopoietic stem cell transplantation early in the course of the disease. Peripheral T-cell lymphoma usually has a poor prognosis. Disease Description Peripheral T-cell lymphoma is a group of invasive tumors with heterogeneous morphological changes with a mature T cell immunophenotype. They accounted for 7% of all non-Hodgkin lymphoma (NHL) cases. Many different clinical syndromes are included in this group of diseases. Diagnosis To diagnose a peripheral T-cell lymphoma or its specific subtype requires a professional hematologist to derive the appropriate biopsy pathology and immunophenotype. Most peripheral T-cell lymphomas are CD4-positive, but rarely CD8-positive, CD4 and CD8 double positive or have NK cell immunophenotype. There are no characteristic genetic abnormalities. However, translocation involving the T cell antigen receptor gene on chromosome 7 or 14 can be detected. A differential diagnosis of suspected peripheral T cell lymphoma includes reactive T cell infiltration. In some cases, the use of T cell receptor gene rearrangement studies has proven to be a monoclonal T cell population that is useful for diagnosis. First-line treatment options for treatment include CHOP, EPOCH and HyperCVAD/MTX-AraC. Younger patients often consider hematopoietic stem cell transplantation early in the course of the disease. The prognosis is unfortunate. Patients with peripheral T-cell lymphoma often have poor prognostic factors, >80% of patients with IPI scores ≥2 and >30% of patients with IPI scores ≥4. As predicted by IPI, peripheral T-cell lymphoma has a poor prognosis, with only 25% of patients surviving for more than 5 years after diagnosis.